Delaney Dennis R Lowers stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Delaney Dennis R reduced its stake in AbbVie Inc by 1.42% during the most recent quarter end. The investment management company now holds a total of 20,780 shares of AbbVie Inc which is valued at $1.3 Million after selling 300 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on May 27, 2016.AbbVie Inc makes up approximately 2.81% of Delaney Dennis R’s portfolio.

Other Hedge Funds, Including , Hemenway Trust Co reduced its stake in ABBV by selling 655 shares or 2.13% in the most recent quarter. The Hedge Fund company now holds 30,095 shares of ABBV which is valued at $1.9 Million. AbbVie Inc makes up approx 0.51% of Hemenway Trust Co’s portfolio.Fdx Advisors boosted its stake in ABBV in the latest quarter, The investment management firm added 47,021 additional shares and now holds a total of 83,212 shares of AbbVie Inc which is valued at $5 Million. AbbVie Inc makes up approx 0.23% of Fdx Advisors’s portfolio.Apg Asset Management N.v. boosted its stake in ABBV in the latest quarter, The investment management firm added 391,277 additional shares and now holds a total of 2,950,864 shares of AbbVie Inc which is valued at $176.1 Million. AbbVie Inc makes up approx 0.38% of Apg Asset Management N.v.’s portfolio.Orbimed Advisors reduced its stake in ABBV by selling 52,800 shares or 0.71% in the most recent quarter. The Hedge Fund company now holds 7,395,700 shares of ABBV which is valued at $441.4 Million. AbbVie Inc makes up approx 4.56% of Orbimed Advisors’s portfolio.Thrivent Financial For Lutherans boosted its stake in ABBV in the latest quarter, The investment management firm added 30,430 additional shares and now holds a total of 80,951 shares of AbbVie Inc which is valued at $5 Million. AbbVie Inc makes up approx 0.03% of Thrivent Financial For Lutherans’s portfolio.

AbbVie Inc opened for trading at $62.59 and hit $63.59 on the upside on Tuesday, eventually ending the session at $63.1, with a gain of 0.45% or 0.28 points. The heightened volatility saw the trading volume jump to 1,09,80,086 shares. Company has a market cap of $102,055 M.

On the company’s financial health, AbbVie Inc reported $1.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.14. The company had revenue of $5958.00 million for the quarter, compared to analysts expectations of $5978.41 million. The company’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. Societe Generale Initiated AbbVie Inc on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $47.Deutsche Bank Initiated AbbVie Inc on Mar 15, 2016 to “Hold”, Price Target of the shares are set at $63.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.